Endpoints News 生物医药· Andrew Dunn·· 1 天前AI 评分36
nChroma Bio提前终止唯一临床试验并裁员50%
nChroma Bio stops its only clinical study early, lays off 50%
AI 导读
基因疗法公司nChroma Bio宣布提前终止其唯一正在进行的临床试验,同时裁减50%员工。两年前,两位波士顿地区生物技术公司CEO合并各自初创企业,希望在基因医学公司低迷的市场环境中求存。
正文
A couple of years ago, two Boston-area biotech CEOs decided to merge their startups, hoping to survive a down market for genetic medicine companies. Jeff …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news